EP3291798A4 - A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof - Google Patents

A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof Download PDF

Info

Publication number
EP3291798A4
EP3291798A4 EP15891266.7A EP15891266A EP3291798A4 EP 3291798 A4 EP3291798 A4 EP 3291798A4 EP 15891266 A EP15891266 A EP 15891266A EP 3291798 A4 EP3291798 A4 EP 3291798A4
Authority
EP
European Patent Office
Prior art keywords
rifabutin
preparation
pharmaceutical formulation
freeze dried
dried pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15891266.7A
Other languages
German (de)
French (fr)
Other versions
EP3291798A1 (en
Inventor
Mitesh Natavarlal Patel
Mafatlal Tribhovandas DAVE
Pranavkumar Jayesh Choksi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gufic Biosciences Ltd
Original Assignee
Gufic Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gufic Biosciences Ltd filed Critical Gufic Biosciences Ltd
Publication of EP3291798A1 publication Critical patent/EP3291798A1/en
Publication of EP3291798A4 publication Critical patent/EP3291798A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP15891266.7A 2015-05-04 2015-09-07 A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof Withdrawn EP3291798A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1770MU2015 2015-05-04
PCT/IN2015/000348 WO2016178240A1 (en) 2015-05-04 2015-09-07 A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof

Publications (2)

Publication Number Publication Date
EP3291798A1 EP3291798A1 (en) 2018-03-14
EP3291798A4 true EP3291798A4 (en) 2019-01-16

Family

ID=57218191

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15891266.7A Withdrawn EP3291798A4 (en) 2015-05-04 2015-09-07 A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof

Country Status (3)

Country Link
EP (1) EP3291798A4 (en)
EA (1) EA201792417A1 (en)
WO (1) WO2016178240A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220103697A (en) * 2019-09-12 2022-07-22 바이오버시스 아게 Rifabutin therapy, uses and compositions
US11344537B2 (en) 2019-09-18 2022-05-31 BioVersys AG Rifabutin treatment methods, uses, and compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013569B1 (en) * 2009-02-24 2010-06-30 Ооо "Научно-Производственный Комплекс "Наносистема"" Pharmaceutical composition of rifabutin for treating tuberculosis and other diseases mediated by helicobacter pylori, method of production thereof and method for treatment thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2550811C (en) * 2003-12-24 2012-05-01 Jane Hirsh Temperature-stable formulations, and methods of development thereof
RU2327457C1 (en) * 2007-06-26 2008-06-27 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Medicinal agent based on rybafutin, agent of antimicrobic action containing nanoparticles, and related method of production
SI2247291T1 (en) * 2008-02-08 2019-03-29 Red Hill Biopharma Ltd. Methods and compositions for treating inflammatory bowel disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013569B1 (en) * 2009-02-24 2010-06-30 Ооо "Научно-Производственный Комплекс "Наносистема"" Pharmaceutical composition of rifabutin for treating tuberculosis and other diseases mediated by helicobacter pylori, method of production thereof and method for treatment thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016178240A1 *

Also Published As

Publication number Publication date
EA201792417A1 (en) 2018-04-30
WO2016178240A1 (en) 2016-11-10
EP3291798A1 (en) 2018-03-14

Similar Documents

Publication Publication Date Title
IL261989A (en) A pharmaceutical formulation of palbociclib and a preparation method thereof
HK1249506A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containging them
EP3139920A4 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
EP3349762A4 (en) Co-crystals of sglt2 inhibitors, process for their preparation and pharmaceutical compositions thereof
EP3130354A4 (en) Posaconazole pharmaceutical composition and preparation method, application and pharmaceutical preparation thereof
HK1254055A1 (en) Methods for the preparation of obeticholic acid and derivatives thereof
EP3694832A4 (en) Extended release pharmaceutical formulation and methods of treatment
EP3295952A4 (en) Pharmaceutical formulation comprising glp-1 analogue and preparation method thereof
EP3438105A4 (en) Diaryl- -lactam compound and preparation method and pharmaceutical use thereof
EP3380525A4 (en) Pharmaceutical formulations and methods of use thereof
EP3485887A4 (en) Injectable pharmaceutical composition of tecovirimat and preparation method thereof
EP3368010A4 (en) Solid dosage form immediate drug release and apparatus and method for manufacture thereof
EP3452441A4 (en) Alpha-truxillic acid derivatives and pharmaceutical compositions thereof
HK1245094A1 (en) Pharmaceutical composition for treatment of depression and preparation method thereof
EP3522889A4 (en) Delayed release pharmaceutical composition of pantoprazole and process for preparation thereof
EP3329897A4 (en) Freeze-drying excipient preparation of arbitrary shape and preparation method therefor
EP3291798A4 (en) A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof
SI2957280T1 (en) Solid pharmaceutical composition of cytisine and process for preparation thereof
EP3383414A4 (en) Herbal pharmaceutical compositions and method of preparation thereof
GB201718483D0 (en) Pharmaceutical composition for treatment of meopausal syndrome and preparation method thereof
EP3307263A4 (en) Pharmaceutical combinations of organo-arsenoxide compounds and mtor inhibitors
IL266938A (en) Pharmaceutical preparation and method for its manufacture
PL3331497T3 (en) A lubricant formulation of carbamoylethyl katira and a process for preparation thereof
EP3305292A4 (en) Pharmaceutical composition of mek inhibitor and preparation method thereof
EP3154528A4 (en) Spray dried compositions having different dissolution profiles and processes for their preparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20171106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181217

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/435 20060101ALI20181207BHEP

Ipc: A61K 9/19 20060101AFI20181207BHEP

Ipc: A61K 47/26 20060101ALI20181207BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190719